Sistemik İlaçların Oküler Yan Etkileri

Peer RF, Shabir N.J Family Med Prim Care. 2018 Mar-Apr;7(2):309-314. doi:10.4103/jfmpc.jfmpc_329_17.

Permpongkosol S. Clin Interv Aging. 2011;6:77-82. doi: 10.2147/CIA.S10252. Epub 2011 Mar 21.

Czakó C., Sándor G., Horváth H., Szepessy Z., Nagy ZZ., Kovács I. Orv Hetil. 2020 Jun;161(23):951-961. doi: 10.1556/650.2020.31723.

Bhatti MT. Orbital syndromes. Semin Neurol. 2007;27:269–287.

Last RJ (ed.) Wolff’s Anatomy of the Eye and Orbit including the Central Connections, Development, and Comparative Anatomy of the Visual Apparatus, 6th edn. (WB Saunders: Philadelphia, 1968): 30

Greve MD. Vitreoretinal surgical anatomy. Peyman GA, Meffert SA, Conway MD. Vitreoretinal Surgical Techniques. 3rd edn. (Informa UK: London, 2007): 2-10.

Fine BS, Yanoff M. Ocular Histology. A text and atlas. New York: Harper & Row;1979;163-168.

Bengisu Ü. Göz hastalıkları,4.baskı: Kornea Anatomisi ve Fizyolojisi. Ankara,Palme yayıncılık, 1998; 69-72.

Tipathi RC, Chalam KV, Cibis GW, Kardon PH, Tipathi BJ, Weleber RG, Wand M. Fundamentals and principles of ophtalmology,American Academy of ophtalmology, Taylor Fran, USA,1999; 150-4.

Özdemir Ö. Kornea transplantasyonu. Medikal Network Oftalmoloji Dergisi 1995; 2.1: 6-9.

Arffa RC. Disease of the cornea ,fourth edition. Mosby Co. 1997, 6-7

William MH. Adler’s Physiology of the eye, Ninth edition, Mosby Co.1992

Orhan M. Korneanın Yapısı, İşlevi ve Muayene Yöntemleri. Medikal NetworkOftalmoloji Dergisi 1994; 4: 306-311.

Cosar CB, Senar AB: Orbscan corneal topography system in evaluating the anteriorstructures of the human eye. Cornea 22:118, 2003.

Bengisu U. Glokom - 9. Bölüm. Göz Hastalıkları (4. Basım).1998:139-158.

Garner LF, Yap MK. Changes in ocular dimensions and refraction with aaccommodation. Ophthalmic Physiol Opt 1997;17:12

Savage JA. American Academy of Ophthalmology, Gonioscopy in theManagement of Glaucoma, Focal Points, San Francisco, AAO 2006;1-14

Apaydın C, Anatomi, Bölüm 1, Temel Göz Hastalıkları (1. Baskı),editörler: Aydın P, Akova YA, Ankara, Günes Kitabevi, 2001;3-25.

Ashton N, Brini A, Smith R. Anatomical studies of trabecular meshwork of Normal human eye. Br J Ophthalmol 1956;40:257 .

Flocks M. The anatomy of the trabecular meshwork as seen in tangential section. Arch Ophthalmol 1956;56:708.

Fine B. Structure of the trabecular meshwork and the canal of Schlemm. Trans Am Acad Ophthalmol Otolaryngol 1966;70:777

Francis BA, Cortes A, Chen J et al. Characteristics of glaucoma drainage implants during dynamic and steady-state flow conditions. Ophthalmology 1998;105:1708-14.

Kozart DM, Anatomic correlates of the retina, in Duane TD, Jaeger EA, eds. Clinical ophthalmology. Harper&Row. 1991: Philadelphia. p. 1-13.

Newell FE, Ophthalmology. Principles and Concepts. 6, Mosby ed. 1986.

Matsumoto, B., J.C. Blanks, and S.J. Ryan, Topographic variations in the rabbit and primate internal limiting membrane. Invest Ophthalmol Vis Sci, 1984. 25.1: p. 71-82.

Green WR, Vitreoretinal interface. In: SJ IR, editor. Retina. 3St Louis Mosby ed. 2000. 1882-960.

Akar S., A.S., Retina embriyogenezi-fizyolojisi, muayene yöntemleri, retina dejeresanları. 2 ed. Akova YA, Q'dwyer PA, editors. Ankara: Güneş tıp kitapevleri. 2011: p. 513-25.

Apaydın C, Anotomi. Aydın P, YA. A, editors. Ankara: Güneş kitabevi. 2001: p. 3-25.

İlhan B, E.B., Retina fizyolojisi. ret-vit. 1998: p. 6:68-73.

Kozart DM, Anotomic Corralates of the Retina. T.D.D, editor. Philadelphia: Clinical Ophthalmology. The Retina Glaucoma. . 1981: p. 1-18.

Özçetin H, Retina Hastalıkları. H.Ö, editor. Bursa:Nobel Tıp Kitabevleri. 2003: p. 232-312.

Marmor MF, Structure, function, and disease of the retinal pigment epithelium. Marmor MF, TJ. W, editors. New York:Oxford University Press. 1998: p. 3-97.

McCaa C. S., The eye and visual nervous sistem:Anatomy, physiology and toxicology. Environ Health Perspect. 1982: p. 44: 1-8.

American Academy of Ophthalmology, Basic and Science Course,Section 12: Retina and Vitreus. 2008.

Edwards, R.B., et al., Synthesis of retinoic acid from retinol by cultured rabbit Muller cells. Exp Eye Res, 1992. 54.4: p. 481-90.

Provis, J.M., Development of the primate retinal vasculature. Prog Retin Eye Res, 2001. 20.6: p. 799-821.

Guyer DR, S.A., Green WR, , The choroid: structural considerations. In: Ryan SJ, Ogden TE, editors. Retina. Volume 1. St.Louis, Baltimore, Toronto: The C.V. Mosby Company. 1989. 17-31.

H, G., Gray’s Anatomy, 37th Edition. Bannister. Williams Warvick Dyson. 1989. 1180-1207.

Fujiwara, T., et al., Enhanced depth imaging optical coherence tomography of the choroid in highly myopic eyes. Am J Ophthalmol, 2009. 148.4: p. 445-50.

Spaide, R.F., H. Koizumi, and M.C. Pozzoni, Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol, 2008. 146.4: p. 496-500.

Krumpaszky, H.G. and V. Klauss, [Cause of blindness in Bavaria. Evaluation of a representative sample from blindness compensation records of Upper Bavaria]. Klin Monbl Augenheilkd, 1992. 200.2: p. 142-6.

Alm A, Bill A. Ocular and optic nerve blood flow at normal and increased intraocular pressures in monkeys (Macacairus): a study with radioactively labelled microspheres including flow determinations in brain and some other tissues. Exp Eye Res. 1973; 15: 15-29

Parver LM, Auker C, Carpenter DO. Choroidal blood flow as a heat dissipating mechanism in the macula. Am J Ophthalmol. 1980; 89: 641e6

Guyer D, S.A., Green W, The Choroid: Structural Considerations. Retina 4th Ed Philadelphia: Elsevier. 2006. 34-42.

CV, N., Developmental Anatomy of the Retinal and Choroidal Vasculature. The Retina and Its Disorders. 2011. 179.

LA, R., Clinical anatomy of the visual system. 3 rd ed: Elsevier. 2005.

Zorab RA, S.H., Dondrea CL, Arturo C, DuCharme N, Tanaka S Fundamentals and Principles of Ophthalmology. Basic and Clinical Science Course. American Academy of Ophthalmology. San Francisco. 2010. 2.

Nickla DL, Wallman J. The multifunctional choroid. Prog Retin Eye Res 2010 Mar; 29 (2): 144-68.

Ernest JT, Choroidal circulation. In: Ryan SJ, Ogden TE, editors. Retina. Volume 1. St.Louis, Baltimore, Toronto: The C.V. Mosby Company. 1989. 67.

Mrejen S, Spaide RF. Optical coherence tomography: imaging of the choroid and beyond. Surv Ophthalmol 2013 Sep-Oct; 58 .5: 387-429.

Harris A, Moss A, Ehrlich R. Chapter 22. The Choroid. Duane’s Ophthalmology CD ROM. Tasman W, Jaeger EA. 2010 Edition, Philadelphia, Lipincott Williams and Wilkins Publishers. 2010.

Chalam KV, Ambati BK, Beaver HA, Grover S, Levine LM, Wells T, Isbey EK. Fundamentals and Principles of Ophthalmology. Basic and Clinical Science Course. Section 2. Singapore, American Academy of Ophthalmology. 64-66. 2011.

O, A.A.o., Retina and vitreous. San Francisco, Calif.: American Academy of Ophthalmology. 2007.

Yoneya, S. and M.O. Tso, Angioarchitecture of the human choroid. Arch Ophthalmol, 1987. 105.5: p. 681-7.

Wangsa-Wirawan, N.D. and R.A. Linsenmeier, Retinal oxygen: fundamental and clinical aspects. Arch Ophthalmol, 2003. 121.4: p. 547-57.

Wallman, J., et al., Moving the retina: choroidal modulation of refractive state. Vision Res, 1995. 35.1: p. 37-50.

Parver, L.M., Temperature modulating action of choroidal blood flow. Eye (Lond), 1991. 5 ( Pt 2): p. 181-5.

Wallman J, Wildsoet C, Xu A, Gottlieb MD, Nickla DL, Marran L, Krebs W, Christensen AM. Moving the retina: choroidal modulation of refractive state. Vision Res 1995 Jan; 35 .1: 37-50

Mrejen, S. and R.F. Spaide, Optical coherence tomography: imaging of the choroid and beyond. Surv Ophthalmol, 2013. 58.5: p. 387-429.

Fraunfelder FT., Sciubba JJ., Mathers WD. The role of medications in causing dry eye. J Ophthalmol 2012:2012:285851. doi: 10.1155/2012/285851. Epub 2012 Aug 27.

Schein OD, Hochberg MC, Muñoz B, Tielsch JM, Bandeen-Roche K, Provost T, Anhalt GJ, West S. Dry eye and dry mouth in the elderly: a population-based assessment. Arch Intern Med. 1999 Jun 28;159(12):1359-63. doi: 10.1001/archinte.159.12.1359.

Paulsen AJ, Cruickshanks KJ, Fischer ME, Huang GH, Klein BE, Klein R, Dalton DS. Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. Am J Ophthalmol. 2014 Apr;157(4):799-806. doi: 10.1016/j.ajo.2013.12.023. Epub 2014 Jan 2.

Apostol S, Filip M, Dragne C, Filip A. Dry eye syndrome. Etiological and therapeutic aspects. Oftalmologia. 2003;59(4):28-31.

Williams IM, Dickinson P, Sum AC. Edrophonium test in myasthenia: quantitative oculography. Clin Exp Neurol. 1986;22:1-12.

Doroshow JH, Locker GY, Gaasterland DE, Hubbard SP, Young RC, Myers CE. Ocular irritation from high-dose methotrexate therapy: pharmacokinetics of drug in the tear film. Cancer. 1981 Nov 15;48(10):2158-62. doi: 10.1002/1097-0142(19811115)48:10<2158::aid-cncr2820481007>3.0.co;2-i.

Düzgün E, Özkur E.The effect of oral isotretinoin therapy on meibomian gland morphology and dry eye tests. J Dermatolog Treat. 2022 Mar;33(2):762-768. doi: 10.1080/09546634.2020.1774041. Epub 2020 Jun 8.

Raizman MB, Hamrah P, Holland EJ, Kim T, Mah FS, Rapuano CJ, Ulrich RG. Drug-induced corneal epithelial changes. Surv Ophthalmol. 2017 May-Jun;62(3):286-301. doi: 10.1016/j.survophthal.2016.11.008. Epub 2016 Nov 24.

Konowal A, Morrison JC, Brown SV, Cooke DL, Maguire LJ, Verdier DV, Fraunfelder FT, Dennis RF, Epstein RJ. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol. 1999 Apr;127(4):403-6. doi: 10.1016/s0002-9394(98)00438-3.

Nik NA, Martin NF, Berler DK. Corneal crystalline deposits and drusenosis associated with IgA-kappa chain monoclonal gammopathy. Am Ophthalmol 1985;17:303–7.

Winterbotham CT, Torczynski E, Horwitz AL, et al. Unusual mucopolysaccharide disorder with corneal and scleral involvement. Am J Ophthalmol 1990;109:544–55.

Moshirfar M, Bennett P, Ronquillo Y. Corneal Dystrophy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2021. http://www.ncbi.nlm.nih.gov/books/NBK557865/

Walter KA, Coulter VL, Palay DA, et al. Corneal endothelial deposits in patients with cytomegalovirus retinitis. Am J Ophthalmol 1996;121:391–6

D'Amico DJ, Kenyon KR. Drug-Induced lipidoses of the cornea and conjunctiva. Int Ophthalmol 1981;4:67–76.

Shayman JA, Abe A. Drug induced phospholipidosis: an acquired lysosomal storage disorder. Biochimica et Biophysica Acta (BBA) -Molecular and Cell Biology of Lipids 2013;1831:602–11.

Stein CA, LaRocca RV, Thomas R, et al. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 1989;7:499–508.

Orlando RG, Dangel ME, Schaal SF. Clinical experience and grading of amiodarone keratopathy. Ophthalmology. 1984 Oct;91(10):1184-7. doi: 10.1016/s0161-6420(84)34165-3.

Hollander DA, Aldave AJ. Drug-induced corneal complications. Curr Opin Ophthalmol 2004;15:541–8.

Bernstein HN. Some iatrogenic ocular diseases from systemically administered drugs. Int Ophthalmol Clin 1970;10:553–619.

Font RL, Sobol W, Matoba A. Polychromatic corneal and conjunctival crystals secondary to clofazimine therapy in a leper. Ophthalmology 1989;96:311–5.

Fraunfelder FT, LaBraico JM, Meyer SM. Adverse ocular reactions possibly associated with isotretinoin. Am J Ophthalmol 1985;100:534–7.

Lal S, Bloom D, Silver B, et al. Replacement of chlorpromazine with other neuroleptics: effect on abnormal skin pigmentation and ocular changes. J Psychiatry Neurosci 1993;18:173–7.

Hollander DA, Aldave AJ. Drug-induced corneal complications. Curr Opin Ophthalmol 2004;15:541–8.

Easterbrook M. Is corneal deposition of antimalarial any indication of retinal toxicity? Can J Ophthalmol 1990;25:249–51.

Dosso A, Rungger-Brändle E. In vivo confocal microscopy in hydroxychloroquine-induced keratopathy. Graefes Arch Clin Exp Ophthalmol 2007;245:318–20.

Nasveld PE, Edstein MD, Reid M, et al. Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Antimicrob Agents Chemother 2010;54:792–8.

Chia PL, John T. Vortex keratopathy presumed secondary to AZD9291. J Thorac Oncol 2015;10:1807–8.

Stokkermans TJ, Goyal A, Bansal P, et al. Chloroquine And Hydroxychloroquine Toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2021. http://www.ncbi.nlm.nih.gov/ books/NBK537086/. (cited 2021 Aug 14). 18 Marmor MF, Carr RE, Easterbrook M, et al.

Dosso A, Rungger-Brändle E. In vivo confocal microscopy in hydroxychloroquine induced keratopathy. Graefes Arch Clin Exp Ophthalmol 2007;245:318–20.

Ingram DV, Jaggarao NS, Chamberlain DA. Ocular changes resulting from therapy with amiodarone. Br J Ophthalmol 1982;66:676–9.

Ghosh M, McCulloch C. Amiodarone-induced ultrastructural changes in human eyes. Can J Ophthalmol 1984;19:178–86.

Ingram DV, Jaggarao NS, Chamberlain DA. Ocular changes resulting from therapy with amiodarone. Br J Ophthalmol 1982;66:676–9.

Passman RS, Bennett CL, Purpura JM, et al. Amiodarone-associated optic neuropathy: a critical review. Am J Med 2012;125:447–53.25

Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007;298:1312–22.

Joshi KM, Gill MK. Amiodarone: a potential risk factor for retinal phototoxicity. Am J Ophthalmol Case Rep 2017;5:119–23.

Mäntyjärvi M, Tuppurainen K, Ikäheimo K. Ocular side effects of amiodarone. Surv Ophthalmol 1998;42:360–6.

Holland EJ, Stein CA, Palestine AG, et al. Suramin keratopathy. Am J Ophthalmol 1988;106:216–20.

Garcia-Schürmann JM, Schulze H, Haupt G, et al. Suramin treatment in hormone- and chemotherapy-refractory prostate cancer. Urology 1999;53:535–41.

Teich SA, Handwerger S, Mathur-Wagh U, et al. Toxic keratopathy associated with suramin therapy. N Engl J Med 1986;314:1455–6.

Stein CA, LaRocca RV, Thomas R, et al. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 1989;7:499–508.

Tarafdar S, Lim LT, Collins CE, et al. Tamoxifen keratopathy as seen with in-vivo confocal microscopy. Semin Ophthalmol 2012;27:27–8.

Noureddin BN, Seoud M, Bashshur Z, et al. Ocular toxicity in low-dose tamoxifen: a prospective study. Eye 1999;13:729–33.

Nayfield SG, Gorin MB. Tamoxifen-associated eye disease. A review. J Clin Oncol 1996 ;;14:1018–26. Mar.

Molina-Ruiz AM, Pulpillo Águeda, Molina-Ruiz RM, et al. Chlorpromazine-induced severe skin pigmentation and corneal opacities in a patient with schizophrenia. Int J Dermatol 2016;55:909–12.

Alexander LJ, Bowerman L, Thompson LR. The prevalence of the ocular side effects of chlorpromazine in the Tuscaloosa Veterans administration patient population. J Am Optom Assoc 1985;56:872–6.

Greiner AC, Berry K. Skin pigmentation and corneal and lens opacities with prolonged chlorpromazine therapy. Can Med Assoc J 1964;90:663–5.

Gokulgandhi MR, Vadlapudi AD, Mitra AK. Ocular toxicity from systemically administered xenobiotics. Expert Opin Drug Metab Toxicol 2012;8:1277–91.

Huff LS, Prado R, Pederson JF, et al. Chlorpromazine-induced skin pigmentation with corneal and lens opacities. Cutis 2014;93:247–50.

S K. Chlorpromazine-induced cataract and corneal pigmentation Indian Journal of Pharmacology 2004;36:323.

Hostetler KY, Richman DD. Studies on the mechanism of phospholipid storage induced by amantadine and chloroquine in Madin Darby canine kidney cells. Biochem Pharmacol 1982;31:3795–9.

Yoshinaka A, Chikama T, Kiuchi Y. Amantadine can induce intra-epithelial deposition in the cornea. Am J Ophthalmol Case Rep 2020;19:100852.

Yoshinaka A, Chikama T, Kiuchi Y. Amantadine can induce intra-epithelial deposition in the cornea. Am J Ophthalmol Case Rep 2020;19:100852.

Karbach U, Kricke J, Meyer-Wentrup F, et al. Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am J Physiol Renal Physiol 2000;279:F679–87.

Fitt A, Dayan M, Gillie RF. Vortex keratopathy associated with ibuprofen therapy. Eye 1996;10:145–6.

Bernstein HN. Some iatrogenic ocular diseases from systemically administered drugs. Int Ophthalmol Clin 1970;10:553–619.

Szmyd L, Perry HD. Keratopathy associated with the use of naproxen. Am J Ophthalmol 1985;99:598.

Fitt A, Dayan M, Gillie RF. Vortex keratopathy associated with ibuprofen therapy. Eye 1996;10:145–6.

Tillmann W, Keitel L. [Indomethacin induced corneal deposits (author's transl)]. Klin Monbl Augenheilkd 1977;170:756–9.

Bron AJ, McLendon BF, Camp AV. Epithelial deposition of gold in the cornea in patients receiving systemic therapy. Am J Ophthalmol 1979;88:354–60.

López JD, del Castillo JMB, López CD, et al. Confocal microscopy in ocular chrysiasis. Cornea 2003;22:573–5.

Paladini I, Menchini U, Mencucci R. Corneal chrysiasis: in vivo confocal microscopy analysis. Eur J Ophthalmol 2010 ;;20:776–9. Jul 1.

Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin Infect Dis 1996;22 Suppl 1:S15–22.

Smith JA, Mueller BU, Nussenblatt RB, et al. Corneal endothelial deposits in children positive for human immunodeficiency virus receiving rifabutin prophylaxis for Mycobacterium avium complex bacteremia. Am J Ophthalmol 1999;127:164–9.

Golchin B, McClellan K. Corneal endothelial deposits secondary to rifabutin prophylaxis for Mycobacterium avium complex bacteraemia. Br J Ophthalmol 2003;87:798–9

Zhang T, Sun CQ, Lin YB, et al. Rifabutin corneal deposits localized to the deep stroma using anterior segment optical coherence tomography. Am J Ophthalmol Case Rep 2020;18:100701.

Dorell L., Ellerton C., Cottrell DG., et al. Toxicity of Clarithromycin in the treatment of Mycobacterium avium complex infection in a patient with AIDS. J Antimicrob Chemother 1994;34:605–6.

Wålinder PE, Gip L, Stempa M. Corneal changes in patients treated with clofazimine. Br J Ophthalmol 1976;60:526–8

Kaur I, Ram J, Kumar B, et al. Effect of clofazimine on eye in multibacillary leprosy. Indian J Lepr 1990;62:87–90.

Barot RK, Viswanath V, Pattiwar MS, et al. Crystalline deposition in the cornea and conjunctiva secondary to long-term clofazimine therapy in a leprosy patient. Indian J Ophthalmol 2011;59:328–9.

Ahn J, Wee WR, Lee JH, et al. Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer. Korean J Ophthalmol 2011;25:355–7.

Arriola-Villalobos P, Benito-PascualB, Díaz-Valle D, et al. Confocal microscopy observation of cornea verticillata after vandetanib therapy for medullary thyroid carcinoma. Cornea 2018;37:789–92.

Nakamura Y, Sotozono C, Kinoshita S. The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis. Exp Eye Res 2001;72:511–7.

Yeh S, Fine HA, Smith JA. Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. Cornea 2009;28:699–702.

Chia PL, John T. Vortex keratopathy presumed secondary to AZD9291. J Thorac Oncol 2015;10:1807–8.

Ritch PS, Hansen RM, Heuer DK. Ocular toxicity from high-dose cytosine arabinoside. Cancer 1983;51:430–2.

Guthoff T, Tietze B, Meinhardt B, et al. Cytosine-arabinoside- İnduced eratopathy: a model of corneal proliferation kinetics. Ophthalmologica 2010;224:308–11.

Krema H, Santiago RA, Schuh A, et al. Cytarabine toxicity of the corneal endothelium. Ann Hematol 2013;92:559–60.

Özcan G, Uçakhan ÖÖ. Cytarabine-induced corneal toxicity: clinical features and relief of symptoms with loteprednol etabonate 0.5% in two patients. Turk J Ophthalmol 2021;51:114–7.

Lochhead J, Salmon JF, Bron AJ. Cytarabine-induced corneal toxicity. Eye 2003;17:677–8

Eaton JS, Miller PE, Mannis MJ, et al. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther 2015;31:589–604.

Beeram M, Krop IE, Burris HA, et al. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer 2012;118:5733–40.

Curtis R, Rullo J. Severe bilateral conjunctivitis with corneal limbal infiltrates associated with Dupilumab treatment. JAMA Ophthalmol 2021;139:e212012.

Lonial S, Nooka AK, Thulasi P, et al. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J 2021;11:103.

Eaton JS, Miller PE, Mannis MJ, et al. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther 2015;31:589–604.

Frings A, Schargus M. Recovery from amiodarone-induced cornea verticillata by application of topical heparin. Cornea 2017;36:1419–22.

Bernstein HN. Some iatrogenic ocular diseases from systemically administered drugs. Int Ophthalmol Clin 1970;10:553–619.

Tripathi RC, Tripathi BJ. The eye. In: Riddell R, editor. Patho logy of drug-induced and toxic diseases. New York (NY): Churchill Livingstone, 1982: 377-456

Li, J., Tripathi, R. C., & Tripathi, B. J. (2008). Drug-Induced Ocular Disorders. Drug Safety, 31(2), 127–141. doi:10.2165/00002018-200831020-00003

Cekic O, Chang S, Tseng JJ, et al. Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol 2005; 139: 993-8

Fraunfelder FT, Fraunfelder FW. Drug-induced ocular side effects. Boston (MA): Butterworth-Heinemann, 2001.

Bron AJ, Tripathi RC, Tripathi BJ. Wolff’s anatomy of the eye and orbit. London (UK): Chapman and Hall, 1997

Grimes P, von Sallmann L, Frichette A. Influence of Myleran on assocell proliferation in the lens epithelium. Invest Ophthalmol 1964; 3: 566-76

Dibas A, Jiang M, Fudala R, et al. Fluorescent protein-labeled glucocorticoid receptor alpha isoform trafficking in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2012;53(6):2938e50

Lewis-Tuffin LJ, Cidlowski JA. The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance. Ann N Y Acad Sci. 2006;1069:1e9

Galon J, Franchimont D, Hiroi N, et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 2002;16(1):61e71

Fingert JH, Ying L, Swiderski RE, et al. Characterization and comparison of the human and mouse GLC1A glaucoma genes. Genome Res. 1998;8:377e84

Patel GC, Phan TN, Maddineni P, et al. Dexamethasoneinduced ocular hypertension in mice: effects of myocilin and route of administration. Am J Pathol. 2017;187(4):713e23

Fan BJ, Wang DY, Tham CC, et al. Gene expression profiles of human trabecular meshwork cells induced by triamcinolone and dexamethasone. Invest Ophthalmol Vis Sci. 2008;49(5):1886e97

Lo WR, Rowlette LL, Caballero M, et al. Tissue differential microarray analysis of dexamethasone induction reveals potential mechanisms of steroid glaucoma. Invest Ophthalmol Vis Sci. 2003;44(2):473e85.

Rozsa FW, Reed DM. Gene expression profile of human trabecular meshwork cells in response to long-term dexamethasone exposure. Mol Vis. 2006;12:125e41.

Clark AF, Wilson K, de Kater AW, et al. Dexamethasoneinduced ocular hypertension in perfusion-cultured human eyes. Invest Ophthalmol Vis Sci. 1995;36:478e89

Clark AF, Wordinger RJ. The role of steroids in outflow resistance. Exp Eye Res. 2009;88:752e9.

Shirato S, Murphy CG. Kinetics of phagocytosis in trabecular meshwork cells. Flow cytometry and morphometry. Invest Ophthalmol Vis Sci. 1989;30(12):2499e511.

Kasetti RB, Maddineni P, Patel PD, et al. Transforming growth factor ß2 (TGFß2) signaling plays a key role in glucocorticoid-induced ocular hypertension. J Biol Chem.2018;293(25):9854e68.

Wilson K, McCartney MD, Miggans ST, Clark AF. Dexamethasone induced ultrastructural changes in cultured human trabecular meshwork cells. Curr Eye Res. 1993;12(9):783e93

Clark AF, Wilson K. Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1994;35(1):281e94.

Clark AF, Miggans ST, Wilson K, et al. Cytoskeletal changes in cultured human glaucoma trabecular meshwork cells. J Glaucoma. 1995;4(3):183e8

Cohen A. Steroid Induced Glaucoma, Glaucoma - Basic and Clinical Concepts, Dr Shimon Rumelt. InTech, London, UK; 2011. ISBN: 978-953-307-591-4.

Armaly MF, Becker B. Intraocular pressure response to topical corticosteroids. Fed Proc. 1965;24(6):1274e8.

Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: II. The effect of dexamethasone on the glaucomatous eye. Arch Ophthalmol. 1963;70:492e9

Gupta S, Shah P, Grewal S, et al. Steroid-induced glaucoma and childhood blindness. Br J Ophthalmol. 2015;99(11):1454e6

Senthil S, Thakur M, Rao HL, et al. Steroid-induced glaucoma and blindness in vernal keratoconjunctivitis. Br J Ophthalmol. 2020;104(2):265e9

Zhang X, Clark AF, Yorio T. Regulation of glucocorticoid responsiveness in glaucomatous trabecular meshwork cells by glucocorticoid receptor-beta. Invest Ophthalmol Vis Sci. 2005;46(12):4607e16.

Zhang X, Ognibene CM, Clark AF, Yorio T. Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta. Exp Eye Res. 2007;84(2):275e84.

Patel GC, Liu Y, Millar JC, Clark AF. Glucocorticoid receptor GRß regulates glucocorticoid-induced ocular hypertension in mice. Sci Rep. 2018;8(1):862.

Garbe E, LeLorier J, Boivin JF, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet. 1997;350(9083):979e82.

Biedner BZ, David R, Grudsky A, Sachs U. Intraocular pressure response to corticosteroids in children. Br J Ophthalmol. 1980;64:430e1.

Hutcheson KA. Steroid-induced glaucoma in an infant. J AAPOS. 2007;11:522e3

Lam DS, Kwok AK, Chew S. Accelerated ocular hypertensive response to topical steroids in children. Br J Ophthalmol. 1997;81:422e3.

Gaston H, Absolon MJ, Thurtle OA, Sattar MA. Steroid responsiveness in connective tissue diseases. Br J Ophthalmol. 1983;67(7):487e90.

Podos SM, Becker B, Morton WR. High myopia and primary open-angle glaucoma. Am J Ophthalmol. 1966;62(6):1038e43.

Becker B, Bresnick G, Chevrette L, et al. Intraocular pressure and its response to topical corticosteroids in diabetes. Arch Ophthalmol. 1966;76(4):477e83.

Spaeth GL. Traumatic hyphema, angle recession, dexamethasone hypertension, and glaucoma. Arch Ophthalmol. 1967;78(6):714e21.

Razeghinejad MR, Katz LJ. Steroid-induced iatrogenic glaucoma. Ophthalmic Res. 2012;47(2):66e80.

Bower T, Samek DA, Mohammed A, et al. Systemic medication usage in glaucoma patients. Can J Ophthalmol. 2018;53(3):242e5.

Adhikary HP, Sells RA, Basu PK. Ocular complications of systemic steroid after renal transplantation and their association with HLA. Br J Ophthalmol. 1982;66(5):290e1.

Garbe E, LeLorier J, Boivin JF, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet. 1997;350(9083):979e82.

Tripathi RC, Kirschner BS, Kipp M, et al. Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure. Gastroenterology.1992;102(6):1957e61.

Acar M, Gedizlioglu M, Koskderelioglu A, et al. Effect of highdose intravenous methyl-prednisolone treatment on intraocular pressure in multiple sclerosis patients with relapse. Eur Neurol. 2012;68(1):20e2.

Gupta SR, Suhler EB, Rosenbaum JT. Intravenous methylprednisolone can cause an acute, vision-threatening rise in intraocular pressure. J Clin Rheumatol. 2010;16(8):397e8

Kiddee W, Trope GE, Sheng L, et al. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol. 2013;58(4):291e310.

Sihota R, Konkal VL, Dada T, et al. Prospective, long-term evaluation of steroid-induced glaucoma. Eye (Lond). 2008;22:26e30.

Phulke S, Kaushik S, Kaur S, Pandav SS. Steroid-induced glaucoma: an avoidable irreversible blindness. J Curr Glaucoma Pract. 2017;11(2):67e72.

Schwartz JT, Reuling FH, Feinleib M, et al. Twin study on ocular pressure following topically applied dexamethasone. II. Inheritance of variation in pressure response. Arch Ophthalmol. 1973;90(4):281e6.

Galin MA, Hirschman H, Gould H, Hofmann I. Does laser trabeculoplasty prevent steroid glaucoma? Ophthalmic Surg Lasers. 2000;31(2):107e10.

Gerometta R, Spiga MG, Borra´ s T, Candia OA. Treatment of sheep steroid-induced ocular hypertension with a glucocorticoid-inducible MMP1 gene therapy virus. Invest Ophthalmol Vis Sci. 2010;51(6):3042e8.

Fraunfelder FW, Rosenbaum JT. Drug‑induced uveitis. Incidence, prevention and treatment. Drug Saf 1997;17:197‑207.

London NJ, Garg SJ, Moorthy RS, Cunningham ET. Drug‑induced uveitis. J Ophthalmic Inflamm Infect 2013;3:43‑60.

Moorthy RS, Moorthy MS, Cunningham ET. Drug‑induced uveitis. Curr Opin Ophthalmol 2018;29:588‑603.

Cordero‐Coma M, Salazar‐Mendez R, Garzo‐Garc I, Yilmaz T. Drug‐induced uveitis. Expert Opin Drug Saf 2015;14:111-26.

Koneru PB, Lien EJ, Koda RT. 31. Oculotoxicities of systemically administered drugs. J Ocul Pharmacol 1986;2:385‑404.

. Mader R, Narendran A, Lewtas J, Bykerk V, Goodman RC, Dickson JR, et al. Systemic vasculitis following influenza vaccination‑report of 3 cases and literature review. J Rheumatol 1993;20:1429‑31. 8.

Worlledge S. Hong Kong treatment services‑royal postgraduate medical school‑british medical research council co‑operative study of rifampicin plus ethambutol in daily and intermittent regimens. The detection of rifampicin‑dependent antibodies. Scand J Respir Dis 1973;84:60‑3.

Jacobs DS, Piliero PJ, Kuperwaser MG, Smith JA, Harris SD, Flanigan TP, et al. Acute uveitis associated with rifabutin use in patients with human immunodeficiency virus infection. Am J Ophthalmol 1994;118:716‑22.

Shafran SD, Deschênes J, Miller M, Phillips P, Toma E. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. MAC Study Group of the Canadian HIV Trials Network. N Engl J Med 1994;330:438‑9.

D’Amato RJ, Alexander GM, Schwartzman RJ, Kitt CA, Price DL, Synder SH. Evidence for neuromelanin involvement in MPTP‑ induced neurotoxicity. Nature 1987;327:324‑6.

Ings RM. The melanin binding of drugs and its implications. Drug Metab Rev 1984;15:1183‑212.

Salazar‑Bookaman MM, Wainer I, Patil PN. Relevance of drug‑melanin interactions to ocular pharmacology and toxicology. J Ocul Pharmacol 1994;10:217‑39.

Broekhuyse RM, Kuhlmann ED, Winkens HJ. Experimental autoimmune anterior uveitis (EAAU). III. Induction by immunization with purified uveal and skin melanins. Exp Eye Res 1993;56:575‑83.

Martins JC, Wilensky JT, Asseff CF, Obstbaum SA, Buerk KM. Corticosteroid‑induced uveitis. Am J Ophthalmol 1974;77:433‑7.

Hargardon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: An overview of FDA approved immune checkpoint inhibitors. Int Immunopharmacol 2018;62:29‑39.

Ehlers S. Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J Rheumatol Suppl 2005;74:35‑39.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239‑45.

Holloway K, Green T. Drug and Therapeutics Committees: A Practical Guide. WHO Department of Essential Drugs and Medicines Policy, Geneva, Switzerland; 2003. Available from: http:// apps.who.int/medicinedocs/pdf/s4882e/s4882e.pdf. [Last accessed on Feb 2020]

Davis JL, Taskintuna I, Freeman WR, Weinberg DV, Feuer WJ, Leonard RE. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 1997;115:733‑7.

Saran BR, Maguire AM, Nichols C, Frank I, Hertle RW, Brucker AJ, et al. Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin. Arch Ophthalmol 1994;112:1159‑65.

Shafran SD, Singer J, Zarowny DP, Deschenes J, Phillips P, Turgeon F, et al. Determinants of rifabutin‑associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: A multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. J Infect Dis 1998;177:252‑5.

Sauty A, Pecherstorfer M, Zimmer‑Roth I, Floroni P, Juillerat L, Markert M, et al. Interleukin‑6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 1996;18:133‑9.

Fraunfelder FW, Fraunfelder FT. Bisphosphonates and ocular inflammation. N Engl J Med 2003;348:1187‑8.

Kristinsson JK, Hannesson OB, Sveinsson O, Thorleifsson H. Bilateral anterior uveitis and retinal haemorrhages after administration of trimethoprim. Acta Ophthalmol Scand 1997;75:314‑5.

Arola O, Peltonen R, Rossi T. Arthritis, uveitis, and Stevens‑Johnson syndrome induced by trimethoprim. Lancet 1998;351:1102.

Okafor LO, Hewins P, Murray PI, Denniston AK. Tubulointerstitial nephritis and uveitis (TINU) syndrome: A systematic review of its epidemiology, demography and risk factors. Orphanet J Rare Dis 2017;12:128.

Mandeville JT, Levinson RD, Holland GN. The tubulointerstitial nephritis and uveitis syndrome. Surv Ophthalmol 2001;46:195‑208.

Li C, Su T, Chu R, Li X, Yang L. Tubulointerstitial nephritis with uveitis in Chinese adults. Clin J Am Soc Nephrol 2014;9:21‑8.

Gaujoux‑Viala C, Giampietro C, Gaujoux T, Ea HK, Prati C, Orcel P, et al. Scleritis: A paradoxical effect of etanercept? Etanercept‑associated inflammatory eye disease. J Rheumatol 2012;39:233‑9.

Ramos‑Casals M, Perez‑Alvarez R, Diaz‑Lagares C, Caudorado MJ, Khamashta MA. BIOGEAS Study Group. Autoimmune diseases induced by biological agents: A double‑edged sword? Autoimmun Rev 2010;9:188‑93.

Ramos‑Casals M, Brito‑Zeron P, Soto MJ, Caudorado MJ, Khamashta MA. Autoimmune diseases induced by TNF‑targeted therapies. Best Pract Res Clin Rheumatol 2008;22:847‑61.

Seve P, Varron L, Broussolle C, Dennis P, Kodjikian L. Sarcoid‑related uveitis occurring during adalimumab therapy. Ocul Immunol Inflamm 2012;20:59‑60.

Taylor HR, Murphy RP, Newland HS, White AT, D’Anna SA, Keyvan Larijani E, et al. Treatment of onchocerciasis. The ocular effects of ivermectin and diethylcarbamazine. Arch Ophthalmol 1986;104:863‑7.

Francis H, Awadzi K, Ottesen EA. The Mazzotti reaction following treatment of onchocerciasis with diethylcarbamazine: Clinical severity as a function of infection intensity. Am J Trop Med Hyg 1985;34:529‑36.

Bird AC, El‑Sheikh H, Anderson J, Fuglsang H. Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate. Br J Ophthalmol 1980;64:191‑200.

Sankar PS, Pasquale LR, Grosskreutz CL. Uveal effusion and secondary angle‑closure glaucoma associated with topiramate use. Arch Ophthalmol 2001;119:1210‑1.

Dhar SK, Sharma V, Kapoor G, Seshadari KP, Chauhan VS. Topiramate induced bilateral anterior uveitis with choroidal detachment and angle closure glaucoma. Med J Armed Forces India 2015;71:88‑91.

Eadie B, Etminan M, Mikelberg FS. Risk of uveitis with oral moxifloxacin: A comparative safety study. JAMA Ophthalmol 2015;133:81‑4.

Willermain F, Deflorenne C, Bouffioux C, Janssens X, Koch P, Caspers L. Uveitis‑like syndrome and iris transillumination after the use of oral moxifloxacin. Eye (Lond) 2010;24:1419.

Sandhu HS, Brucker AJ, Ma L, Vander Beek BL. Oral fluoroquinolones and the risk of uveitis. JAMA Ophthalmol 2016;134:38‑43.

Conrady CD, Larochelle M, Pecen P, Palestine A, Shakoor A, Singh A. Checkpoint inhibitor‑induced uveitis: A case series. Graefes Arch Clin Exp Ophthalmol 2018;256:187‑91.

Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune && therapy: Systemic indications and ophthalmic side effects. Retina 2018;38:1063‑78.

Arai T, Harada K, Usui Y, Irisawa R, Tsuboi R. Case of acute anterior uveitis and Vogt‑ Koyanagi‑Harada syndrome‑like eruptions induced by nivolumab in a melanoma patient. J Dermatol 2017;44:975‑6.

Matsuo T, Yamasaki O. Vogt‑Koyanagi‑Harada disease‑like posterior uveitis in the course of nivolumab (anti‑PD‑1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep 2017;5:694‑700.

Fujimura T, Kambayashi Y, Tanita K, Sato Y, Hidaka T, Otsuka A, et al. HLA‑DRB1*04:05 in two cases of Vogt‑Koyanagi‑Harada disease‑like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy. J Dermatol 2018;45:735‑7.

Bricout M, Petre A, Amini‑Adle M, Bezza W, Seve P, Kodjikian L, et al. Vogt‑Koyanagi‑Harada‑like syndrome complicating pembrolizumab treatment for metastatic melanoma. J Immunother 2017;40:77‑82.

Nguyen M, Islam M, Lim S, Sahu A, Tamjid B. Pembrolizumab induced ocular hypotony with near complete vision loss, interstitial pulmonary fibrosis and arthritis. Front Oncol 2019;9:944.

Choe CH, McArthur GA, Caro I, Kempen JH, Amravadi RK. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol 2014;158:831‑7.

Guedj M, Queant A, Funck‑Brentano E, Kramkimel N, Lellouch J, Monnet D, et al. Uveitis in patients with late‑ stage cutaneous melanoma treated with vemurafenib. JAMA Ophthalmol 2014;132:1421‑5.

Joshi L, Karydis A, Gemenetzi M, Shao EH, Taylor SR. Uveitis as a result of MAP kinase pathway inhibition. Case Rep Ophthalmol 2013;4:279‑82.

Kuniyoshi K, Hatsukawa Y, Kimura S, Fujino T, Ohguro H, Nakai R, et al. Acute bilateral photoreceptor degeneration in an infant after vaccination against measles and rubella. JAMA Ophthalmol 2017;135:478‑82.

Benage M, Fraunfelder FW. Vaccine‑associated uveitis. Mo Med 2016;113:48‑52.

Kuniyoshi K, Hatsukawa Y, Kimura S, Fujino T, Ohguro H, Nakai R, et al. Acute bilateral photoreceptor degeneration in an infant after vaccination against measles and rubella. JAMA Ophthalmol 2017;135:478‑82. Benage M, Fraunfelder FW. Vaccine‑associated uveitis. Mo Med 2016;113:48‑52.

Cunningham ET, Moorthy RS, Fraunfelder FW, Zierhut M. Va c c i n e ‑ a s s o c i a t e d u ve i t i s . O c u l Immu n o l I n f l a mm 2019;27:517‑20.

Willis ED, Woodward M, Brown E, Popmihajlov Z, Saddier P, Annunziato PW, et al. Herpes zoster vaccine live: A 10 year review of post‑marketing safety experience. Vaccine 2017;35:7231‑9.

Guex‑Crosier Y, Chamot L, Zografos L. Chorioretinitis induced by intravesical Bacillus Calmette‑Guérin (BCG) instillations for urinary bladder carcinoma. Klin Monatsbl Augenheilkd 2003;220:193‑5.

Llorenç V, Mesquida M, Molins B, González‑Martín J, Sainz de la Maza M, Adán A. Bacillus calmette‑guérin infection and cytotoxicity in the retinal pigment epithelium. Ocul Immunol Inflamm 2018;26:786‑92.

Knopf HL. Recurrent uveitis after influenza vaccination. Ann Ophthalmol 1991;23:213‑4.

Escott S, Tarabishy AB, Davidorf FH. Multifocal choroiditis following simultaneous hepatitis A, typhoid, and yellow fever vaccination. Clin Ophthalmol Auckl NZ 2013;7:363‑5.

Stangos A, Zaninetti M, Petropoulos I, Baglivo E, Pournaras C. Multiple evanescent white dot syndrome following simultaneous hepatitis‑A and yellow fever vaccination. Ocul Immunol Inflamm 2006;14:301‑4.

Garip A, Diedrichs‑Möhring M, Thurau SR, Deeg CA, Wildner G. Uveitis in a patient treated with Bacille‑Calmette‑Guérin: Possible antigenic mimicry of mycobacterial and retinal antigens. Ophthalmology 2009;116:2457‑62.

Fraunfelder FW, Suhler EB, Fraunfelder FT. Hepatitis B vaccine and uveitis: An emerging hypothesis suggested by review of 32 case reports. Cutan Ocul Toxicol 2010;29:26‑9. 76. Fried M, Conen D, Conzelmann M, Steinemann E. Uveitis after hepatitis B vaccination. Lancet Lond Engl 1987;2:631‑2.

Sood AB, O’Keefe G, Bui D, Jain N. Vogt‑Koyanagi‑Harada disease associated with hepatitis B vaccination. Ocul Immunol Inflamm 2019;27:524‑7.

Erguven M, Guven S, Akyuz U, Bilgiç O, Laloglu F. Optic neuritis following hepatitis B vaccination in a 9‑year‑old girl. J Chin Med Assoc JCMA 2009;72:594‑7.

Holt HD, Hinkle DM, Falk NS, Fraunfelder FT, Fraunfelder FW. Human papilloma virus vaccine associated uveitis. Curr Drug Saf 2014;9:65‑8.

Khalifa YM, Monahan PM, Acharya NR. Ampiginous choroiditis following quadrivalent human papilloma virus vaccine. Br J Ophthalmol 2010;94:137‑9.

Sawai T, Shimizu M, Sakai T, Yachie A. Tubulointerstitial nephritis and uveitis syndrome associated with human papillomavirus vaccine. J Pediatr Ophthalmol Strabismus 2016;53:190‑1914.

Gonome T, Suzuki Y, Metoki T, Takahashi S, Nakazawa M. Acute posterior multifocal placoid pigment epitheliopathy and granulomatous uveitis following influenza vaccination. Am J Ophthalmol Case Rep 2016;4:60‑3.

Mendrinos E, Baglivo E. Acute posterior multifocal placoid pigment epitheliopathy following influenza vaccination. Eye Lond Engl 2010;24:180‑1.

Abou‑Samra A, Tarabishy AB. Multiple evanescent white dot syndrome following intradermal influenza vaccination. Ocul Immunol Inflamm 2019;27:528‑30.

Blanche P, Decrette C, Sicard D. Development of uveitis following vaccination for influenza. Clin Infect Dis Off Publ Infect Dis Soc Am 1994;19:979.

Wells MB, Garg S. Bilateral panuveitis after influenza vaccination. Retin Cases Brief Rep 2009;3:386‑87.

Tao Y, Chang L‑B, Zhao M, Li X‑X. Two cases of exudative retinal detachment and uveitis following H1N1 influenza vaccination. Chin Med J (Engl) 2011;124:3838‑40.

Kim M. Vogt‑Koyanagi‑Harada syndrome following influenza vaccination. Indian J Ophthalmol 2016;64:98.

Manusow JS, Rai A, Yeh S, Mandelcorn ED. Two cases of panuveitis with orbital inflammatory syndrome after influenza vaccination. Can J Ophthalmol 2015;50:e71‑4.

Williams GS, Evans S, Yeo D, Al‑bermani A. Retinal artery vasculitis secondary to administration of influenza vaccine. BMJ Case Rep 2015;2015:bcr2015211971.

Blumberg S, Bienfang D, Kantrowitz FG. A possible association between influenza vaccination and small‑vessel vasculitis. Arch Intern Med 1980;140:847‑8.

Knopf HL. Recurrent uveitis after influenza vaccination. Ann Ophthalmol 1991;23:213‑4.

Parafita‑Fernández A, Parafita MA. Bilateral iritis after vaccine for bladder cancer. Optom Vis Sci Off Publ Am Acad Optom 2015;92:e368‑70.

Jacob M, Gambrelle J, Fleury J, Durieu I, Kodjikian L, Duquesne N,et al. [Panuveitis following intravesical bacille Calmette‑Guerin therapy]. J Fr Ophtalmol 2006;29:552‑5.

Hegde V, Dean F. Bilateral panuveitis and optic neuritis following Bacillus Calmette‑Guérin (BCG) vaccination. Acta Paediatr Oslo Nor 1992 2005;94:635‑6.

Uppal GS, Shah AN, Tossounis CM, Tappin MJ. Bilateral panuveitis following intravesical BCG immunotherapy for bladder carcinoma. Ocul Immunol Inflamm 2010;18292‑6.

Sedaghat M, Zarei‑Ghanavati S, Shokoohi S, Ghasemi A. Panuveitis and dermal vasculitis following MMR vaccination. East Mediterr Health J 2007;13:470‑4.

Ferrini W, Aubert V, Balmer A, Munier FL, Abouzeid H. Anterior uveitis and cataract after rubella vaccination: A case report of a 12‑month‑old girl. Pediatrics 2013;132:e1035‑8.

Suzuki J, Goto H, Komase K, Abo H, Fujii K, Otsuki N, et al. Rubella virus as a possible etiological agent of Fuchs heterochromic iridocyclitis. Graefes Arch Clin Exp Ophthalmol 2010;24:1487‑91.

Hwang CW Jr, Steigleman WA, Saucedo‑Sanchez E, Tuli SS. Reactivation of herpes zoster keratitis in an adult after varicella zoster vaccination. Cornea 2013;32:508‑9.

Santana-Cabrera L, Fernandez-Tagarro EJ, Amo-Nolasco B, et al. Unilateral mydriasis secondary to ipratropium bromide in a critically ill patient. J Emerg Trauma Shock 2012; 5:199–200.

Hannon B, Jennings V, Twomey M, O’Reilly M. Transdermal hyoscine induced unilateral mydriasis. BMJ Case Rep 2012; 2012:pii:bcr0820114697.

Lee DT, Jenkins NL, Anastasopulos AJ, et al. Transdermal scopolamine and perioperative anisocoria in craniofacial surgery: a report of 3 patients. J Craniofac Surg 2013; 24:470–472.

Polomsky M, Smereck J. Unilateral mydriasis due to hemorrhoidal ointment. J Emerg Med 2014; 43:e11–e15.

Cheng KL, Chan YC, Mak TW, et al. Chinese herbal medicine-induced anticholinergic poisoning in Hong Kong. Hong Kong Med J 2013; 19:38–41.

Matouskova O, Slanar O, Chytil L, Perlik F. Pupillometry in healthy volunteers as a biomarker of tramadol efficacy. J Clin Pharm Ther 2011; 36:513–517.

Wirostko BM, Tressler C, Hwang LF, et al. Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomized, double masked, placebo controlled trial and open label extension. BMJ 2012; 344:e554.

Oishi A, Miyamoto K, Kashii S, Yoshimura N. Photopsia as a manifestation of digitalis toxicity. Can J Ophthalmol 2006; 41:603–604.

Butler VP Jr, Odel JG, Rath E, et al. Digitalis-induced visual disturbances with therapeutic serum digitalis concentrations. Ann Intern Med 1995; 123:676–680.

Poulas K, Koutsouraki E, Kordas G, et al. Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by D-penicillamine. J Neuroimmunol 2012; 250:94–98.

Congeni JP, Kirkpatrick RB. Pegylated interferon induced myasthenia crisis: a case report. J Clin Neuromuscul Dis 2013; 14:123–125.

Glick ZR, Vaphiades MS, Northington ME. OnabotulinumtoxinA unmasking myasthenia gravis. Dermatol Surg 2013; 39:472–473.

Blichfeldt-Lauridsen L, Hansen BD. Anesthesia and myasthenia gravis. Acta Anaesthesiol Scand 2012; 56:17–22.

Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf 2011;34:839–847.

Dournon N, Buffet P, Caumes E, et al. Artesunate for severe acute Plasmodium falciparum infection in a patient with myasthenia gravis. Am J Trop Med Hyg 2012; 87:435–436.

Pascuzzi RM. Medications and myasthenia gravis (a reference for healthcare professionals). Department of Neurology Indiana University School of Medicine. Copyright 2000 by Myasthenia Gravis Foundation of America.

Gilhus NE. Is it safe to use statins in patients with myasthenia gravis? Nat Clin Pract Neurol 2009; 5:8–9.

Hammerstrom AE, Howell J, Gulbis A, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol 2013; 88:301–305.

Abbas O, Shamseddin A, Temraz S, Haydar A. Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient. BMJ Case Rep 2013; 2013:ii:bcr2012007995. doi: 10.1136/bcr-2012-007995.

Oshikawa G, Kojima A, Doki N, et al. Bortezomib-induced posterior reversible encephalopathy syndrome in a patient with newly diagnosed multiple myeloma. Intern Med 2013; 52:111–114.

Wei R, Jin L, Huang J, Luo B. Desmopressin-induced posterior reversible encephalopathy syndrome. Intern Med 2012; 51:3081–3084.

Stu¨bgen JP. Posterior reversible encephalopathy syndrome (PRES) after granulocyte-colony stimulating factor (G-CSF) therapy: a report of 2 cases. J Neurol Sci 2012; 321:35–38.

Porcello Marrone LC, Marrone BF, Pascoal TA, et al. Posterior reversible encephalopathy syndrome associated with FOLFOX chemotherapy. Case Rep Oncol Med 2013; 2013:306983. doi: 10.1155/2013/306983.

Foerster R, Welzel T, Debus J, et al. Posterior reversible leukoencephalopathy syndrome associated with pazopanib. Case Rep Oncol 2013; 6:204–208.

Kushner BH, Modak S, Basu EM, et al. Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody. Cancer 2013; 119:2789–2795.

Al Bu Ali WH. Ciprofloxacin-associated posterior reversible encephalopathy. BMJ Case Rep 2013; 2013:ii:bcr2013008636. doi: 10.1136/bcr-2013-008636.

Dotan G, Goldstein M, Stolovitch C, Kesler A. Pediatric pseudotumor cerebri associated with low serum levels of vitamin A. J Child Neurol 2013. [Epub ahead of rint].

Besch D, Makowski C, Steinborn MM, et al. Visual loss without headache in children with pseudotumor cerebri and growth hormone treatment. Neuropediatrics 2013; 44:203–207.

Biousse V, Bruce BB, Newman NJ. Neuro-ophthalmology update on the pathophysiology and management of idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 2012; 83:488–494.

Re´ mi J, Hu¨ ttenbrenner A, Feddersen B, Noachtar S. Carbamazepine but not pregabalin impairs eye control: a study on acute objective CNS side effects in healthy volunteers. Epilepsy Res 2010; 88:145–150.

Gosala Raja Kukkuta S, Srinivas M, Raghunandan N, et al. Reversible vertical gaze palsy in sodium valproate toxicity. J Neuroophthalmol 2013; 33:202–203.

Carstairs SD, Schneir AB. Opsoclonus due to diphenhydramine poisoning. N Engl J Med 2010; 363:e40.

Guiloff RJ, Whiteley A, Kelly RE. Organic convergence spasm. Acta Neurol Scand 1980; 61:252–259.

Veerapandiyan A, Gallentine WB, Winchester SA, et al. Oculogyric crises secondary to lamotrigine overdosage. Epilepsia 2011; 52:e4–e6.

Arumugam J, Vijayalakshmi AM. Metoclopramide-induced oculogyric crisis presenting as encephalitis in a young girl. Indian J Pharmacol 2012; 44:266–267.

Bayram E, Bayram MT, Hiz S, Turkmen M. Cefixime-induced oculogyric crisis. Pediatr Emerg Care 2012; 28:55–56.

Caulfield MP. Muscarinic receptors: characterisation, coupling and function. Pharmacol Therap 1993; 58:319–379.

Enriquez-de-Salamanca A, Calonge M. Muscarinic receptors in the ocular surface. Curr Opin Allergy Clin Immunol 2006; 6:379–382.

Nietgen GW, Schmidt J, Hesse L, et al. Muscarinic receptor functioning and distribution in the eye: molecular basis and implications for clinical diagnosis and therapy. Eye 1999; 13:285–300.

. O’Neill EC, Danesh-Meyer HV, Connell PP, et al. The optic nerve head in acquired optic neuropathies. Nat Rev Neurol 2010; 6:221–236.

Smolen JS, Landewe R Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease- modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis 2014; 73(3): 492–509.

Fanouriakis A,Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis 2019; 78(6): 736–745.

Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat- Chalumeau N et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann. Rheum. Dis 2019; 78(6):1296–1304.

Vivino FB, Carsons SE,Foulks G, Daniels TE, Parke A, Brennan MT et al. New treatment guidelines for Sjogren’s disease. Rheum. Dis. Clin. North. Am 2016; 42(3): 531–551.

Messai, A. in Emerging Research on Bioinspired Materials Engineering (ed. Bououdina, M.) IGI Global, 2016 160–196.

Cutler DJ, MacIntyre AC, Tett SE. Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials. Agents Actions Suppl 1988. 24, 142–157.

Rynes RI, Bernstein HN. Ophthalmologic safety profile of antimalarial drugs. Lupus 1993 2, S17–S19.

Lee MG, Kim SJ, Ham DI, et al. Macular retinal ganglion cell inner plexiform layer thickness in patients on hydroxychloroquine therapy. Invest Ophthalmol Vis Sci 2014;56:396–402.

Sisternes L, Hu J, Rubin DL, Marmor MF. Localization of damage in progressive hydroxychloroquine retinopathy on and off the drug: inner versus outer retina, parafovea versus peripheral fovea. Invest Ophthalmol Vis Sci 2015;56:3415–26.

Melles RB, Marmor MF. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology 2015;122:110–6.

Lee DH, Melles RB, Joe SG, et al. Pericentral hydroxychloroquine retinopathy in Korean patients. Ophthalmology 2015;122:1252–6.

Melles RB, Marmor MF. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology 2015;122:110–6.

Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014;132:1453–60.

Kellner S, Weinitz S, Farmand G, Kellner U. Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation. Br J Ophthalmol 2014;98:200–6.

Marmor MF, Hu J. Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol 2014;132:1105–12

Shroyer NF, Lewis RA, Lupski JR. Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease? Am J Ophthalmol 2001;131:761–6.

Grassman F, Bergholz R, Mändl J. Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy). BMC Ophthalmol 2015;15:18.

Miller FS, Bunt-Milam AH, Kalina RE. Clinical ultrastructural study of thioridazine retinopathy, Ophthalmology 1982;89:1478–1488.

Richa S,YazbekJC.Ocular adverse effects of common psychotropic agents:a review. CNS Drugs. 2010;24(6):501–526.

FraunfelderFT. Drug-induced OcularSideEffects. 4thed.Philadelphia,USA:LippincottWilliams&Wilkins;1996.

SchwartzSG,MielerWF.Medicationsandretinaltoxicity. Ophthalmol ClinNorthAm. 2002;15(4):517–528.

Scholz, R. T., & Sunness, J. S. (2014). DARK ADAPTATION ABNORMALITIES AND RECOVERY IN ACUTE THIORIDAZINE TOXICITY. Retinal Cases & Brief Reports, 8(1), 45–49. doi:10.1097/icb.0000000000000000

V.C. Barry ,An organic chemist’s approach to the chemotherapy of tuberculosis Ir. J. Med. Sci. (1926-1967), 26 (10) (1951), pp. 453-473

V.C. Barry, J.G. Belton, M.L. Conalty, J.M. Denneny, D.W. Edward, J.F. O'Sullivan, D. Twomey, F. Winder. A new series of phenazines (rimino-compounds) with high antituberculosis activity Nature, 179 (4568) (1957), pp. 1013-1015.

R. O'Connor, J.F. O'Sullivan, R. O'Kennedy. The pharmacology, metabolism, and chemistry of clofazimine Drug Metab. Rev., 27 (4) (1995), pp. 591-614.

S.G. Browne, L.M. Hogerzeil. B 663" in the treatment of leprosy. Preliminary report of a pilot trial Lepr. Rev., 33 (1962), pp. 6-10.

WHO Study Group on Chemotherapy of Leprosy for Control Programmes & World Health Organization. (‎1982)‎. Chemotherapy of leprosy for control programmes : report of a WHO study group [‎meeting held in Geneva from 12 to 16 October 1981]‎. World Health Organization. (https://iris.who.int/handle/10665/38984).

In vitro activity of clofazimine against rapidly growing nonchromogenic mycobacteria Antimicrob. Agents Chemother., 29 (5) (1986), pp. 951-952.

S.A. McGuffin, P.S. Pottinger, J.P. Harnisch Clofazimine in nontuberculous mycobacterial infections: a growing niche Open Forum Infect. Dis., 4 (3) (2017), p. ofx147.

D. Falzon, H.J. Schünemann, E. Harausz, L. González Angulo, C. Lienhardt, E. Jaramillo, K. Weyer World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update Eur. Respir. J., 49 (3) (2017), p. 1602308.

A. Van Deun, A.K. Maug, M.A. Salim, P.K. Das, M.R. Sarker, P. Daru, H.L. Rieder Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis Am. J. Respir. Crit. Care Med, 182 (5) (2010), pp. 684-692.

K.J. Aung, A. VanDeun, E. Declercq, M.R. Sarker, P.K. Das, M.A. Hossain, H.L. Rieder. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients Int J. Tube Lung Dis., 18 (10) (2014), pp. 1180-1187.

M.C. Cholo, M.T. Mothiba, B. Fourie, R. Anderson. Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline J. Antimicrob. Chemother., 72 (2) (2017), pp. 338-353.

M.C. Cholo, H.C. Steel, P.B. Fourie, W.A. Germishuizen, R. Anderson. Clofazimine: current status and future prospects J. Antimicrob. Chemother., 67 (2) (2012), pp. 290-298.

(who.int/publications/m/item/haftalık -epidemiyolojik-updategüncelleme-on-covid-19-20 Temmuz-2023).

W. Wan, S. Zhu, S. Li, W. Shang, R. Zhang, H. Li, W. Liu, G. Xiao, K. Peng, L. Zhang. High-throughput screening of an FDA-approved drug library identifies inhibitors against arenaviruses and SARS-CoV-2 ACS Infect. Dis., 7 (6) (2021), pp. 1409-1422.

Craythorn JM, Swartz M, Creel DJ. Clofazimine-induced bull’s-eye retinopathy. Retina. 1986;6(1):50-52

Cunningham CA, Friedberg DN, Carr RE. Clofazamine-induced generalized retinal degeneration. Retina. 1990;10(2):131-134.

Forster DJ, Causey DM, Rao NA. Bull’s eye retinopathy and clofazimine. Annals of internal medicine. 1992;116(10):876-877.

Aronson JK. An account of foxglove and its medical uses 1785–1985. Oxford: Oxford University press; 1985.

McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847.

Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. Guidelines-CPG ESCCfP, document R: 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation developed with the special contribution of the European Heart Rhythm Association. Europace Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2012;14(10):1385–413.

Pautas E, Lopez C, Gouronnec A, Gravelaine S, Peyron I, Lapostolle F. Focus on digitalis intoxication in the elderly. Report of a case treated with digoxin-specific Fab antibody fragments. Geriatrie et psychologie neuropsychiatrie du vieillissement. 2012;10(4):355–63.

Jackson HJ, Zerfas LG. A case of yellow vision associated with digitalis poisoning. Boston Med Surg J. 1925;192:890–3.

Renard D, Rubli E, Voide N, Borruat FX, Rothuizen LE., Spectrum of digoxin-induced ocular toxicity: a case report and literature review. BMC Res Notes. 2015 Aug 23;8:368. doi: 10.1186/s13104-015-1367-6.

Aronson JK. An account of foxglove and its medical uses 1785–1985. Oxford: Oxford University press; 1985.

Capellan P, Mahrous MA, Kovacs KD. OCT Findings in Presumed Digoxin Retinal Toxicity. Ophthalmology Retina. 2021; 5(11):1173-1175.

G. M. Brittenham, “Iron-chelating therapy for transfusional iron overload,” The New England Journal of Medicine, vol. 364, no. 2, pp. 146–156, 2011.

J. B. Porter, “A risk-benefit assessment of iron-chelation therapy,” Drug Safety, vol. 17, no. 6, pp. 407–421, 1997.

A. Jacobs, “Iron overload: clinical and pathologic aspects,” Seminars in Hematology, vol. 14, no. 1, pp. 89–113, 1977.

P. Ackrill, A. J. Ralston, J. P. Day, and K. C. Hodge, “Successful removal of aluminium from patient with dialysis encephalopathy,” The Lancet, vol. 2, no. 8196, pp. 692–693, 1980.

H. K. Stummvoll, H. Graf, and V. Meisinger, “Effect of desferrioxamine on aluminum kinetics during hemodialysis,” Mineral and Electrolyte Metabolism, vol. 10, no. 4, pp. 263–266, 1984.

S.-H. Chen,D.-C. Liang, H.-C. Lin, S.-Y. Cheng, L.-J. Chen, and H.-C. Liu, “Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients,” Journal of Pediatric Hematology/Oncology, vol. 27, no. 12, pp. 651–653, 2005.

N. F. Olivieri, J. R. Buncic, E. Chew et al., “Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions,”The New England Journal ofMedicine, vol. 314, no. 14, pp. 869–873, 1986.

A. Cohen, M.Martin, J.Mizanin, D. F. Konkle, and E. Schwartz, “Vision and hearing during deferoxamine therapy,” The Journal of Pediatrics, vol. 117, no. 2, pp. 326–330, 1990.

R. Haimovici, D. J. D’Amico, E. S. Gragoudas, S. Sokol, and Deferoxamine Retinopathy Study Group, “The expanded clinical spectrumof deferoxamine retinopathy,” Ophthalmology, vol. 109, no. 1, pp. 164–171, 2002.

Y.-L. Chan, C.-W.W. Chu, K.-W. Chik, L.-M. Pang,M.-K. Shing, and C.-K. Li, “Deferoxamine-induced dysplasia of the knee: sonographic features and diagnostic performance compared with magnetic resonance imaging,” Journal of Ultrasound inMedicine, vol. 20, no. 7, pp. 723–728, 2001.

S.-H. Chen,D.-C. Liang, H.-C. Lin, S.-Y. Cheng, L.-J. Chen, and H.-C. Liu, “Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients,” Journal of Pediatric Hematology/Oncology, vol. 27, no. 12, pp. 651–653, 2005.

N. F. Olivieri, J. R. Buncic, E. Chew et al., “Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions,”The New England Journal ofMedicine, vol. 314, no. 14, pp. 869–873, 1986.

S. C. Davies, J. L. Hungerford, G. B. Arden, R. E. Marcus, M. H. Miller, and E. R. Huehns, “Ocular toxicity of high-dose intravenous desferrioxamine,” The Lancet, vol. 2, no. 8343, pp. 181–184, 1983.

D. R. Blake, P. Winyard, J. Lunec et al., “Cerebral and ocular toxicity induced by desferrioxamine,” The Quarterly Journal of Medicine, vol. 56, no. 219, pp. 345–355, 1985.

F. Viola, G. Barteselli, L. Dell’Arti et al., “Abnormal fundus autofluorescence results of patients in long-termtreatment with deferoxamine,” Ophthalmology, vol. 119, no. 8, pp. 1693–1700, 2012.

S. de Virgiliis, M. Congia,M. P. Turco et al., “Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia,” Archives of Disease in Childhood, vol. 63, no. 3, pp. 250–255, 1988.

A. E. Leure-duPree and C. J. McClain, “The effect of severe zinc deficiency on the morphology of the rat retinal pigment epithelium,” Investigative Ophthalmology and Visual Science, vol. 23, no. 4, pp. 425–434, 1982.

D. Tate and D. Newsome, “A novel zinc compound (zinc monocysteine) enhances the antioxidant capacity of human retinal pigment epithelial cells,” Current Eye Research, vol. 31, no. 7-8, pp. 675–683, 2006.

G. B. Arden, B.Wonke, C. Kennedy, and E. R. Huehns, “Ocular changes in patients undergoing long-term desferrioxamine treatment,” British Journal of Ophthalmology, vol. 68, no. 12, pp. 873–877, 1984.

C. Bene, A. Manzler, D. Bene, and G. Kranias, “Irreversible ocular toxicity from single “challenge” dose of deferoxamine,” Clinical Nephrology, vol. 31, no. 1, pp. 45–48, 1989.

D. R. Blake, P. Winyard, J. Lunec et al., “Cerebral and ocular toxicity induced by desferrioxamine,” The Quarterly Journal of Medicine, vol. 56, no. 219, pp. 345–355, 1985.

F. Viola, G. Barteselli, L. Dell’Arti et al., “Multimodal imaging in deferoxamine retinopathy,” Retina, vol. 34, pp. 1428–1438, 2014.

A. H. S. Rahi, J. L. Hungerford, and I. Ahmed, “Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings,” The British Journal of Ophthalmology, vol. 70, no. 5, pp. 373–381, 1986.

N. F. Olivieri and G. M. Brittenham, “Iron-chelating therapy and the treatment of thalassemia,” Blood, vol. 89, no. 3, pp. 739–761, 1997.

Whitcup SM, Butler KM, Pizzo PA, Nussenblatt RB. Retinal lesions in children treated with dideoxyinosine. N Engl J Med 1992;326:1226–1227.

Nguyen BY, Shay LE, Wyvill KM, et al. A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection. J Infect Dis 1993;168:810–817.

Cobo J, Ruiz MF, Figueroa MS, et al. Retinal toxicity associated with didanosine in HIV-infected adults. AIDS 1996;10:1297–1300.

Gabrielian A, MacCumber MM, Kukuyev A, et al. Didanosine-associated retinal toxicity in adults infected with human immunodeficiency virus. JAMA Opthalmol 2013;131:255–259.

Haug S., Wong RW., Day S., Choudhry N., Sneed S., Prasad P., Read S., McDonald RH., Agarwal A., Davis J., Sarraf D. Didanosine retinal toxicity. Retina, 2016 Dec:36 Suppl 1:S159-S167. doi: 10.1097/IAE.0000000000001267.

Sun Y, Liu WZ, Liu T, et al. Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res 2015; 35:600–604.

Sun Y, Liu WZ, Liu T, et al. Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res 2015; 35:600–604.

Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 2011;75:50–83.

Eggermont AM, Spatz A, Robert C. Cutaneous melanoma.Lancet 2014;383:816–827

Satyamoorthy K, Li G, Gerrero MR, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003;63:756–759.

Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 2012;150:251–263.

Ji Z, Flaherty KT, Tsao H. Targeting the RAS pathway in melanoma. Trends Mol Med 2012;18:27–35.

Stjepanovic, N, Velazquez-Martin, JP, Bedard PL. Ocular toxicities of MEK inhibitors and other targeted therapies. Annals of Oncology. 2016;27(6), 998-1005.

Mendez-Martinez S, Calvo P, Ruiz-Moreno O, Baron NP, Bueno JL, Ruiz MRG et al. Ocular adverse events associated with MEK inhibitors Review. Retina 2019; 39(8):1435-1450.

Huang W, Yang AH, Matsumoto D, et al. PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. J Ocul Pharmacol Ther 2009; 25: 519–530.

Jiang Q, Cao C, Lu S, et al. MEK/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cells. Int J Mol Med 2009; 23: 771–777.

McCannel TA, Chmielowski B, Finn RS, Goldman J, Ribas A, Wainberg ZA et al. Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. JAMA Ophthalmol 2014; 132(8):1005–1009. 39.

Francis JH, Habib LA, Abramson DH, Yannuzzi LA, Heinemann M, Gounder MM et al. Clinical and morphologic characteristics of MEK inhibitor–associated retinopathy: differences from central serous chorioretinopathy. Ophthalmology 2017;124(12):1788– 1798.

Urner-Bloch U, Urner M, Jaberg-Bentele N, et al. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: long-term ophthalmic effects. Eur J Cancer 2016;65:130–138.

Vinberg, F.; Chen, J.; Kefalov, V.J. Regulation of calcium homeostasis in the outer segments of rod and cone photoreceptors. Prog.Retin. Eye Res. 2018, 67, 87–101.

Bischoff, E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int. J. Impot. Res. 2004, 16, S11–S14.

Boswell-Smith, V.; Spina, D.; Page, C.P. Phosphodiesterase inhibitors. Br. J. Pharmacol. 2006, 147, 252–257.

Zucchi, A.; Costantini, E.; Scroppo, F.I.; Silvani, M.; Kopa, Z.; Illiano, E.; Petrillo, M.G.; Cari, L.; Nocentini, G. The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue. Andrology 2019, 7, 804–817.

Bhogal, S.; Khraisha, O.; Al Madani, M.; Treece, J.; Baumrucker, S.J.; Paul, T.K. Sildenafil for Pulmonary Arterial Hypertension. Am. J. Ther. 2019, 26, e520–e526.

Ferguson, J.E.; Carson, C.C. Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons. Arab J. Urol. 2013, 11, 222–229.

Anderson, K. PDE5 inhibitors-pharmacology and clinical applications 20 years after sildenafil discovery. Br. J. Pharmacol. 2018,175, 2554–2565.

Corona, G.; Rastrelli, G.; Burri, A.; Jannini, E.A.; Maggi, M. The safety and efficacy of Avanafil, a new 2nd generation PDE5i:Comprehensive review and meta-analysis. Expert Opin. Drug Saf. 2016, 15, 237–247.

Taylor, J.; Baldo, O.B.; Storey, A.; Cartledge, J.; Eardley, I. Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors. BJU Int. 2009, 103, 1392–1395.

Bischoff, E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int. J. Impot. Res. 2004, 16, S11–S14.

Cordell WH, Maturi RK, Costigan TM, Marmor MF, Weleber RG, Coupland SG, Danis RP, McGettigan JW Jr, Antoszyk AN, Klise S, Sides GD: Retinal effects of 6 months of daily use of tadalafil or sildenafil. Arch Ophthalmol 2009;127:367–373.

Marmor MF, Kessler R: Sildenafil (viagra) and ophthalmology. Surv Ophthalmol 1999; 44:153–162

Coleman, D.J.; Lee,W.; Chang, S.; Silverman, R.H.; Lloyd, H.O.; Daly, S.; Tsang, S.H. Treatment of Macular Degeneration with Sildenafil: Results of a Two-Year Trial. Ophthalmologica 2018, 240, 45–54.

Matieli, L.; Berezovsky, A.; Salomão, S.R.; Allemann, N.; Martins, E.N.; Hirai, F.E.; Ota-Arakaki, J.; Morales, M.S.A.; de Freitas, D. Ocular toxicity assessment of chronic sildenafil therapy for pulmonary arterial hypertension. Graefe’s Arch. Clin. Exp. Ophthalmol.2016, 254, 1167–1174.

Luu JK, Chappelow AV, McCulley TJ, Marmor MF: Acute effects of sildenafil on the electroretinogram and multifocal electroretinogram. Am J Ophthalmol 2001; 132: 388–394.

Quiram P, Dumars S, Parwar B, Sarraf D. Viagra-associated serous macular detachment. GraefesArchClinExpOphthalmol. 2005;243(4):339–344.

Dowlati A, Crosby L, Remick SC, et al. Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer—the use of complete response rate as the primary endpoint in phase II trials. Lung Cancer 2001;32:155–162.

Katz BJ, Ward JH, Digre KB, Crell DJ, Mamalis N. Persistent severe visual and electroretinographic abnormalities after intravenous Cisplatin therapy. J euroophthalmol 2003; 23(2): 132–135.

Khawly JA, Rubin P, Petros W, Jaffe GJ. Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer. Ophthalmology 1996; 103(1): 87–95.

Langevin S, Chang JS and Chang S. Serous retinopathy associated with Cisplatin treatment. Retin Cases Brief Rep 2019; 13(3):211–214.

Lin teh B., Duggan R., Leslie T. Bilateral Subfoveal Serous Detachment Following Cisplatin Chemotherapy. Eur J Ophtalmol. 2021 Sep;31(5):NP19-NP22. doi: 10.1177/1120672120921373.

Carter SK, Newman JW: Nitrosoureas: 1,3x=req- bis(2-chloroethyl)-1-nitrosourea (NSC-409962:BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1x=req- nitrosourea (NSC-79037; CCNU). Cancer Chemother Rep 1968;1(pt 3):115-151.

DeVita V, Carbone P, Owens A, et al: Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC-409962). Cancer Res 1965;25:1876x=req- 1881.

Kupersmith MJ, Seiple WH, Holopigian K, Noble K, Hiesiger E, Warren F. Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine. Am J Ophthalmol 1992;113(4):435–8.

Davies AJ, Kelly SP, Naylor SG, Bhatt PR, Mathews JP, Sahni J et al. Adverse ophthalmic reaction in poppers users: case series of “poppers maculopathy.” Eye. 2012;26(11):1479-1486.

Gruener AM, Jeffries MA, El Housseini Z, Whitefield L. Poppers maculopathy. Lancet. 2014;384(9954):1606.

Van Bol LB, Kurt RA, Keane PA, Pal B, Sivaprasad S. Clinical Phenotypes of Poppers Maculopathy and Their Links to Visual and Anatomic Recovery. Ophthalmology 2017;124(9):1425-1427.

Clemens CR, Alten F, Loos D, Uhlig CE, Heiduschka P, Eter N. Poppers maculopathy or retinopathy? Eye(Lond).2015;29(1):148-149.

Isabelle Audo I, El Sanharawi M, Vignal-Clermont C, Villa A, Morin A, Conrath J et al. Foveal damage in habitual poppers users. Arch Ophthalmol. 2011;129(6):703-708.

Pahlitzsch M, Mai C, Joussen AM, Bergholz R. Poppers maculopathy: complete restitution of macular changes in OCT after drug abstinence. Semin Ophthalmol. 2016;31(5):479-484.

Davies AJ, Kelly SP, Naylor SG, Bhatt PR, Mathews JP, Sahni J et al. Adverse ophthalmic reaction in poppers users: case series of “poppers maculopathy.” Eye. 2012;26(11):1479-1486.

F. Neu, “Les oed`emes maculaires cystoides (OMC),” Bulletin de la Societe Belge d’Ophtalmologie, vol. 304, pp. 71–76, 2007.

T. G. Rotsos and M. M. Moschos, “Cystoid macular edema,”Journal of Clinical Ophthalmology, vol. 2, no. 4, pp. 919–930, 2008.

J. J. Kanski, Oftalmologia Clinica, Elsevier, New York, NY, USA, 2008.

A. S.Wierzbicki, “Niacin: the only vitamin that reduces cardiovascular events,” International Journal of Clinical Practice, vol. 65, no. 4, pp. 379–385, 2011.

V. S. Kamanna and M. L. Kashyap, “Mechanism of action of niacin,”American Journal of Cardiology, vol. 101, no. 8, pp. 20B–26B, 2008. [5] A. S.Wierzbicki, “Niacin: the only vitamin that reduces cardiovascular events,” International Journal of Clinical Practice, vol. 65, no. 4, pp. 379–385, 2011.

D.M. Capuzzi, J.M.Morgan,O.A.BruscoJr., andC.M. Intenzo, “Niacin dosing: relationship to benefits and adverse effects,” Current Atherosclerosis Reports, vol. 2, no. 1, pp. 64–71, 2000.

M. Lukasova, J. Hanson, S. Tunaru, and S. Offermanns, “Nicotinic acid (niacin): new lipid-independentmechanisms of action and therapeutic potentials,” Trends in Pharmacological Sciences, vol. 32, no. 12, pp. 700–707, 2011.

F. W. Fraunfelder, F. T. Fraunfelder, and D. R. Illingworth, “Adverse ocular effects associated with niacin therapy,” British Journal of Ophthalmology, vol. 79, no. 1, pp. 54–56, 1995. [9] F. W. Fraunfelder, “Ocular side effects from herbal medicines and nutritional supplements,” American Journal of Ophthalmology, vol. 138, no. 4, pp. 639–647, 2004.

J. D. Gass, “Nicotinic acid maculopathy. 1973,” Retina, vol. 23, no. 6, pp. 500–510, 2003.

D. M. Devaney, “Maculopathy induced by nicotinic acid,” Clinical Eye and Vision Care, vol. 10, no. 2, pp. 67–71, 1998.

S. Karakashian and C. D. Bayliff, “Niacin-induced cystoid macular edema,” The Canadian Journal of Hospital Pharmacy, vol. 54, no. 1, pp. 35–36, 2001.

M. Mizutani, C. Gerhardinger, and M. Lorenzi, “Muller cell changes in human diabetic retinopathy,” Diabetes, vol. 47, no.3, pp. 445–449, 1998.

Q. Li and D. G. Puro, “Diabetes-induced dysfunction of the glutamate transporter in retinal M¨uller cells,” Investigative Ophthalmology & Visual Science, vol. 43, no. 9, pp. 3109–3116, 2002.

Wani MC, Taylor HL, Wall ME, et al. Plant Antitumor Agents.VI. The isolationand structure of taxol, a novel antileukemic and antitumor agent from Taxus Brevifolia 2. J Am Chem Soc 1971; 3:2325–2327.

Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport,and cell death. J Clin Oncol 1999; 17:1061–1070. https://doi. org/10.1200/JCO.1999.17.3.1061.

Béhar A, Pujade Lauraine E, Maurel A, et al. The pathophysiological mechanism of fluid retention in advanced cancer patients treatedwith docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol 1997; 43: 653–658.

Noguchi Y, Kawashima Y, Maruyama M, et al. Risk factors for eye disorders caused by paclitaxel: A retrospective study. Biol Pharm Bull 2018; 41:1694–1700. https://doi.org/10.1248/bpb.b18-00444.

Joshi MM, Garretson BR. Paclitaxel maculopathy. Arch Ophthalmol 2007; 125: 709–710. https://doi.org/10.1001/ archopht.125.5.709.

Smith S, Benz M, Brown D. Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol 2008; 126: 1605–1606. https://doi.org/10.1001/ archopht.126.11.1605

Matsuoka N, Hasebe H, Mayama T, et al. Sub-tenon injections of triamcinolone acetonide had limited effect on cystoid macular edema secondary to nanoparticle albumin-boundpaclitaxel (Abraxane).Case Rep Ophthalmol Med 2015:181269. https://doi.org/10.1155/2015/181269.

Rahman HT, Yeh S, Bergstrom CS. Cystoid macular edema without leakage secondary to nab- paclitaxel(abraxane): Clinical experience with intravitreal bevacizumab. J Ocul Pharmacol Ther 2013; 29: 360–362. https://doi.org/10.1089/ jop.2011.0178

Kuznetcova TI, Cech P, Herbort CP. The mystery of angiographically silent macular oedema due to taxanes. Int Ophthalmol 2012; 32:299–304. https://doi.org/10.1007/ s10792-012-9558-9.

Sridhar J, Shahlaee A, Ehmann D, et al. En face optical coherence tomography and optical coherence tomography angiography imaging of taxane-associated cystoid macular edema. Ophthalmic Surg Lasers Imaging Retin 2016, 47:176–179.https://doi.org/10.3928/23258160- 20160126-12.

Di Pippo M., Di Staso F., De Ponte C., Fragiotta S., Abdolrahimzade S. Nab-paclitaxel Related Cystoid Macular Edema. Clin Ter 2022; 173 (4):377-383 doi: 10.7417/CT.2022.2449

Walton C, King R, Rechtman L, et al.: Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020, 26:1816-21. 10.1177/1352458520970841.

Reich DS, Lucchinetti CF, Calabresi PA: Multiple sclerosis. N Engl J Med. 2018, 378:169-80. 10.1056/NEJMra1401483.

Milo R, Kahana E: Multiple sclerosis: geoepidemiology, genetics and the environment . Autoimmun Rev. 2010, 9:A387-94. 10.1016/j.autrev.2009.11.010.

Zorzon M, Zivadinov R, Nasuelli D, et al.: Risk factors of multiple sclerosis: a case-control study . Neurol Sci. 2003, 24:242-7. 10.1007/s10072-003-0147-6.

Compston A, Coles A: Multiple sclerosis. Lancet. 2008, 372:1502-17. 10.1016/S0140-6736(08)61620 -7.

Brownlee WJ, Hardy TA, Fazekas F, Miller DH: Diagnosis of multiple sclerosis: progress and challenges . Lancet. 2017, 389:1336-46. 10.1016/S0140-6736(16)30959-X .

Jacobs LD, Beck RW, Simon JH, et al.: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000, 343:898-904.10.1056/NEJM200009283431301.

Chun J, Hartung HP: Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis . Clin Neuropharmacol. 2010, 33:91-101. 10.1097/WNF.0b013e3181cbf825.

Fernández O, Izquierdo G, Aguera E, et al.: Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study. Mult Scler J Exp Transl Clin. 2020, 6:2055217320957358.10.1177/2055217320957358.

Brinkmann V, Davis MD, Heise CE, et al.: The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002, 277:21453-7. 10.1074/jbc.C200176200

Willis MA, Cohen JA: Fingolimod therapy for multiple sclerosis . Semin Neurol. 2013, 33:37-44. 10.1055/s-0033-1343794.

Kappos L, Radue EW, O'Connor P, et al.: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010, 362:387-401. 10.1056/NEJMoa0909494.

Nolan R, Gelfand JM, Green AJ: Fingolimod treatment in multiple sclerosis leads to increased macular volume. Neurology. 2013, 80:139-44. 10.1212/WNL.0b013e31827b9132.

Haseloff RF, Blasig IE, Bauer HC, Bauer H: In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells in vitro. Cell Mol Neurobiol. 2005, 25:25-39.10.1007/s10571-004-1375-x.

Fukuoka H, Kojima K, Iwama A, Okumura T, Sotozono C: Fingolimod-associated severe bilateral cystoid macular edema. Am J Ophthalmol Case Rep. 2022, 26:101553. 10.1016/j.ajoc.2022.101553.

Afshar AR, Fernandes JK, Patel RD, Ksiazek SM, Sheth VS, Reder AT, Hariprasad SM: Cystoid macular edema associated with fingolimod use for multiple sclerosis. JAMA Ophthalmol. 2013, 131:103-7. 10.1001/jamaophthalmol.2013.570.

Cugati S, Chen CS, Lake S, Lee AW. Fingolimod and macular edema: Pathophysiology, diagnosis, and management. Neurol Clin Pract. 2014;4(5):402-9.

Norgaard TL, Andersen CU, Hilt C, Andersen CU. Macular oedema and changes in macular thickness in multiple sclerosis patients treated with fingolimod. Basic Clin Pharmacol Toxicol. 2020;126(6):492-7.

Husmann R, Davies JB, Ghannam M, Berry B, Kelkar P. Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications. Clin Mol Allergy. 2020;18:3.

Sonne SJ, Smith BT. Incidence of uveitis and macular edema among patients taking fingolimod 0.5 mg for multiple sclerosis. J Ophthalmic Inflamm Infect. 2020;10(1):24.

Kaiser-Kupfer, M.I.; Lippman, M.E. Tamoxifen retinopathy. Cancer Treat. Rep. 1978, 62, 315–320.

Toimela, T.; Salminen, L.; Tähti, H. Effects of Tamoxifen, Toremifene and Chloroquine on the Lysosomal Enzymes in Cultured Retinal Pigment Epithelial Cells. Basic Clin. Pharmacol. Toxicol. 1998, 83, 246–251.

Kaiser-Kupfer, M.I.; Lippman, M.E. Tamoxifen retinopathy. Cancer Treat. Rep. 1978, 62, 315–320. Vinding, T.; Nielsen, N.V. Retinopathy caused by treatment with tamoxifen in low dosage. Acta Ophthalmol. 2009, 61, 45–50.

Kim, H.-A.; Lee, S.; Eah, K.S.; Yoon, Y.H. Prevalence and Risk Factors of Tamoxifen Retinopathy. Ophthalmology 2019, 127, 555–557.

Crisóstomo, S.; Vieira, L.; Cardigos, J.; Fernandes, D.H.; Luís, M.E.; Nunes, S.; Morujão, I.; Anjos, R.; Flores, R.M.R.P. Tamoxifeninduced chorioretinal changes. Retina 2020, 40, 1185–1190.

Szabelska P. , Paczwa K., Ciszewska J., Rozycki R. Gołebiewska J. Unilateral Tamoxifen-Induced Retinopathy as a Consequence of Breast Cancer Treatment—Multimodal Imaging Value. Diagnostics 2023, 13, 1250.

Harnois C, Cortin P, Samson J, Boudreault G, Malenfant M,Rousseau A. Static perimetry in canthaxanthin maculopathy. Arch Ophthalmol Chic Ill 1960. 1988;106(1):58-60.

Cortin P, Corriveau LA, Rousseau AP, Tardif Y, Malenfant M, Boudreault G: Maculopathie en paillettes d’or. Can J Ophthalmol 1982; 17: 103–106.

Sujak A. Interactions between canthaxanthin and lipid membranes-possible mechanisms of canthaxanthin toxicity. Cell Mol Biol Lett. 2009;14(3):395-410.

Mazze RI: Fluorinated anaesthetic nephrotoxicity: an update. Can Anaesth Soc J 1984; 31:16--22.

Meredith TA.,Wright JD. , Gammon JA., et al. Ocular involvement in primary hyperoxaluria. Arch Ophtalmol 1984;102-584-587.

Novak MA, Roth AS, Levine MR. Calcium oxalate retinopathy associated with methoxyflurane abuse. Retina Phila Pa. 1988;8(4):230-236.

Conklin JD. The pharmacokinetics of nitrofurantoin and its related bioavailability. Antibiot Chemother. 1978;25:233-252.

Ibanez HE, Williams DF, Boniuk I. Crystalline retinopathy associated with long-term nitrofurantoin therapy. Arch Ophthalmol Chic Ill 1960. 1994;112(3):304-305.

Shah VA, Cassell M, Poulose A, Sabates NR. Talc retinopathy. Ophthalmology 2008;115(4):755.

Murphy SB, Jackson WB, Pare JA. Talc retinopathy. Can J Ophthalmol 1978;13(3):152–156.

AtLee WE. Talc and cornstarch emboli in eyes of drug abusers. JAMA 1972;219(1):49–51.

Kresca LJ, Goldberg MF, Jampol LM. Talc emboli and retinal neovascularization in a drug abuser. Am J Ophthalmol 1979:87(3):334–339.

Brucker AJ. Disk and peripheral retinal neovascularization secondary to talc and cornstarch emboli. Am J Ophthalmol.1979;88(5):864-867.

Borden EC, Parkinson D. A perspective on the clinical effectiveness and tolerance of interferon-alpha. Semin Oncol. 1998;25 Suppl 1):3–8.

Hayasaka S, Nagaki Y, Matsumoto M, Sato S. Interferon associated retinopathy. Br J Ophthalmol. 1998;82(3):323–325.

Lai CH, Yang YH, Chen PC, King YC, Liu CY. Retinal vascular complications associated with interferon-ribavirin therapy for chronic hepatitis C: A population-based study. Pharmacoepidemiol Drug Saf. 2018;27(2):191–198.

d’Alteroche L, Majzoub S, Lecuyer AI, Delplace MP, Bacq Y. Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis. J Hepatol. 2006;44(1):56–61.

Tu KL, Bowyer J, Schofield K, Harding S. Severe interferon associated retinopathy. Br J Ophthalmol. 2003;87(2):247–248.

Nagaoka T, Sato E, Takahashi A, Yokohama S, Yoshida A. Retinal circulatory changes associated with interferon-induced retinopathy in patients with hepatitis C. Invest Ophthalmol Vis Sci. 2007;48(1):368–375.

Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3’, 5’-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood. 1981;57(5):946–955.

Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: An update on recent clinical findings. Obstet Gynecol Surv. 2008;63(3):163–181.

Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19(2):376–388.

Ruddle JB, Harper CA, Honemann D, Seymour JF, Prince HM. A denileukin diftitox (Ontak) associated retinopathy? Br J Ophthalmol. 2006;90(8):1070–1071.

Takeuchi M, Keino H, Kezuka T, Usui M, Taguchi O. Immune responses to retinal self-antigens in CD25 (+) CD4(+) regulatory T-cell-depleted mice. Invest Ophthalmol Vis Sci. 2004;45(6):1879–1886.

Lubow M, Grzybowski DM, Awad H. Denilieukin diftitox vision loss is not posterior ischemic optic neuropathy. Leuk Lymphoma. 2008;49(2):370–3.

Soushi S, Kobayashi F, Obazawa H, Kigasawa K, Shiraishi K, Itakura M, et al. Evaluation of risk factors of interferon-associated retinopathy in patients with type C chronic active hepatitis. Nippon Ganka Gakkai Zasshi. 1996;100(1):69–76.

Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–2417.

Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 2006;46(4):171-181.

Sheyman AT, Wald KJ, Pahk PJ, Freund KB. Gemcitabine associated retinopathy and Nephropathy. Retin Cases Brief Rep 2014;8:107–109.

Banach MJ, Williams GA. Purtscher retinopathy and necrotizing vasculitis with gemcitabine therapy. Arch Ophthalmol. 2000;118(5):726-7.

Batra S, Wadhwa J, Vaid AK, Sharma N. Old drugs: new complications. BMJ Case Rep. 2013;2013.

Shahab N, Haider S, Doll DC. Vascular toxicity of antineoplastic agents. Semin Oncol 2006;33:121–138.

Warren RP, Jr, Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol. 1986;4:74–9.

Warrell RP, Jr., Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol. 1986;4(1):74-9.

Spriggs DR, Stopa E, Mayer RJ, Schoene W, Kufe DW. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res. 1986;46(11):5953-8.

Bishop RJ, Ding X, Heller CK, 3rd, Illei G, Caruso R, Cunningham D, et al. Rapid vision loss associated with fludarabine administration. Retina.2010;30(8):1272-7.

Chee YL, Culligan DJ, Olson JA, Molyneaux P, Kurtz JB, Watson HG. Sight-threatening varicella zoster virus infection after fludarabine treatment.Br J Haematol. 2000;110(4):874-5.

Bos PM., Deutman AF. Acute macular neuroretinopathy. Am J Oph¬thalmol. 1975;80(4):573-584.

Turbeville SD, Cowan LD, Gass JM. Acute macular neuroretinopa¬thy: a review of the literature. Surv Ophthalmol. 2003;48(1):1-11.

Vessey MP, Hannaford P, Mant J, Painter R, Frith P, Chappel D. Oral contraception and eye disease: findings in two large cohort studies. Br J Ophthalmol.1998;82(5):538-42.

Song D, Nadelmann J, Yu Y, VanderBeek BL. Association of retinal vascular occlusion with women filling a prescription for female hormone therapy. JAMA ophthalmology. 2021;139(1):42-8.

Shanti, C.M., Lucas, C.E., 2003. Cocaine and the critical care challenge. Crit Care Med 31(6), 1851-1859.

Ren, H., Du, C., Yuan, Z., Park, K., Volkow, N.D., Pan, Y., 2012. Cocaine-induced cortical microischemia in the rodent brain: clinical implications. Mol Psychiatry 17(10),1017-1025.

Chow, C.C., Shah, R.J., Lim, J.I., Chau, F.Y., Hallak, J.A., Vajaranant, T.S., 2013. Peripapillary retinal nerve fiber layer thickness in sickle-cell hemoglobinopathies using spectral-domain optical coherence tomography. Am J Ophthalmol 155(3), 456-464 e452.

Introini, U., Casalino, G., Querques, G., Bagini, M., Bandello, F., 2015. Acute macular neuroretinopathy following intranasal use of cocaine. Acta Ophthalmol 93(3), e239-240.

Kannan B, Balaji V, Kummararaj S, Govindarajan K. Cilioretinal artery occlusion following intranasal cocaine insufflations. Indian Journal of Ophthalmology. 2011;59(5):388.